2026-04-13T16:52:53Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/103812025-10-24T08:28:06Zcom_2072_451660com_2072_378040col_2072_451662
RECERCAT
author
GARCIA GARCIA, MARIA JOSE
author
Rivero, Montserrat
author
Miranda-Bautista, Jose
author
Mesonero, Francisco
author
LEO-CARNERERO, EDUARDO
author
Monfort Miquel, David
author
Baston Rey, Iria
2025-10-24T08:28:06Z
2025-10-24T08:28:06Z
2023-09-29T11:46:29Z2023-09-29T11:46:29Z2021-09-26
http://hdl.handle.net/11351/10381
Crohn disease; Ustekinumab; Colitis, UlcerativeEnfermedad de Crohn; Ustekinumab; Colitis ulcerosaMalaltia de Crohn; Ustekinumab; Colitis ulcerosaBackground: The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab.
Aims: To evaluate the impact of biologics on the risk of PC.
Methods: A retrospective study was performed in 37 centres. Patients treated with biologics within 12 weeks before surgery were considered "exposed". The impact of the exposure on the risk of 30-day PC and the risk of infections was assessed by logistic regression and propensity score-matched analysis.
Results: A total of 1535 surgeries were performed on 1370 patients. Of them, 711 surgeries were conducted in the exposed cohort (584 anti-TNF, 58 vedolizumab and 69 ustekinumab). In the multivariate analysis, male gender (OR: 1.5; 95% CI: 1.2-2.0), urgent surgery (OR: 1.6; 95% CI: 1.2-2.2), laparotomy approach (OR: 1.5; 95% CI: 1.1-1.9) and severe anaemia (OR: 1.8; 95% CI: 1.3-2.6) had higher risk of PC, while academic hospitals had significantly lower risk. Exposure to biologics (either anti-TNF, vedolizumab or ustekinumab) did not increase the risk of PC (OR: 1.2; 95% CI: 0.97-1.58), although it could be a risk factor for postoperative infections (OR 1.5; 95% CI: 1.03-2.27).
Conclusions: Preoperative administration of biologics does not seem to be a risk factor for overall PC, although it may be so for postoperative infections.The authors report assistance from Equipo 3datos for the statistical analysis; this support was funded by the Spanish Working Group in Crohn’s Disease and Ulcerative Colitis (GETECCU).
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Crohn, Malaltia de
Colitis ulcerosa
Cirurgia
DISEASES::Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases::Crohn Disease
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized::Ustekinumab
DISEASES::Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Colitis::Colitis, Ulcerative
ENFERMEDADES::enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal::enfermedad de Crohn
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados::ustekinumab
ENFERMEDADES::enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::colitis::colitis ulcerosa
Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion